The most common adverse reaction to zoledronic acid (ZOL) infusion is the acutephase reaction (APR), characterized by transient, usually mild, flu-like symptoms. Previous treatment with oral aminobisphosphonates (BPs) was reported as an independent protective factor for APR, and an association between APR and 25-hydroxyvitamin D (25[OH]D) levels in BP-naïve patients treated with ZOL was identified. The aim of our study was to confirm this association and to see if the association was different in patients previously treated with oral BPs compared with BP-naïve patients, and to investigate the role of 25(OH)D for the time of APR onset.
Acute phase reactions after zoledronic acid infusion: protective role of 25-OH vitamin D and previous oral bisphosphonate therapy / C. Crotti, N.B. Watts, M. De Santis, A. Ceribelli, G. Fabbriciani, F. Cavaciocchi, B. Marasini, C. Selmi, M. Massarotti. - In: ENDOCRINE PRACTICE. - ISSN 1530-891X. - (2018). [Epub ahead of print] [10.4158/EP161638.OR]
Acute phase reactions after zoledronic acid infusion: protective role of 25-OH vitamin D and previous oral bisphosphonate therapy
C. Crotti;C. Selmi;
2018
Abstract
The most common adverse reaction to zoledronic acid (ZOL) infusion is the acutephase reaction (APR), characterized by transient, usually mild, flu-like symptoms. Previous treatment with oral aminobisphosphonates (BPs) was reported as an independent protective factor for APR, and an association between APR and 25-hydroxyvitamin D (25[OH]D) levels in BP-naïve patients treated with ZOL was identified. The aim of our study was to confirm this association and to see if the association was different in patients previously treated with oral BPs compared with BP-naïve patients, and to investigate the role of 25(OH)D for the time of APR onset.File | Dimensione | Formato | |
---|---|---|---|
ep161638.or.pdf
accesso riservato
Tipologia:
Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione
206.73 kB
Formato
Adobe PDF
|
206.73 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.